Scientists reprogram Patients' own cells to hunt deadly cancer mutations

NCT ID NCT06478251

First seen Jan 04, 2026 · Last updated Apr 05, 2026 · Updated 13 times

Summary

This early-stage study is testing a new type of personalized cell therapy for people with advanced solid tumors that have specific KRAS gene mutations. Doctors will collect a patient's own immune cells, genetically modify them in a lab to recognize and attack cancer cells with KRAS mutations, and then infuse them back into the patient. The main goals are to see if this treatment is safe and to find the right dose, while also checking for any early signs that it might shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUMOR, SOLID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Zhejiang University school of Medicine

    RECRUITING

    Hangzhou, Zhejiang, China

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.